<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920436</url>
  </required_header>
  <id_info>
    <org_study_id>02-2018-035</org_study_id>
    <nct_id>NCT03920436</nct_id>
  </id_info>
  <brief_title>Effects of Oral Ingestion of Drinking Water Using a Tumbler That Emits Far Infrared Rays on Metabolic Profile</brief_title>
  <official_title>Effects of Oral Ingestion of Drinking Water Using a Tumbler That Emits Far Infrared Rays at Room Temperature on Metabolic Profile in Adults: a RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
      the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays
      at room temperature on metabolic profile in adults for 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
      the effects of oral ingestion of drinking water using a tumbler that emits far infrared rays
      at room temperature on metabolic profile in adults for 8 weeks; the safety of the compound
      are also evaluate. The Investigators examine lipid profile, glucose, liver and renal function
      at baseline, as well as after 4, 8 weeks of intervention. Thirty adults were administered
      either 1.8 L of drinking water using a tumbler that emits far infrared rays at room
      temperature or drinking water using a sham-tumbler each day for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Change from baseline level of LDL-C at 8 weeks</time_frame>
    <description>Change of LDL-C during 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aspartate transaminase (AST)</measure>
    <time_frame>Change from baseline level of AST at 8 weeks</time_frame>
    <description>Change of AST during 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine</measure>
    <time_frame>Change from baseline level of creatinine at 8 weeks</time_frame>
    <description>Change of creatinine during 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homeostasis model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>Change from baseline level of HOMA-IR at 8 weeks</time_frame>
    <description>Change of HOMA-IR during 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Change from baseline level at 8 weeks</time_frame>
    <description>Change of body weight during 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free fatty acid</measure>
    <time_frame>Change from baseline level at 8 weeks</time_frame>
    <description>Change of free fatty acid during 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alanine transaminase (ALT)</measure>
    <time_frame>Change from baseline level of ALT at 8 weeks</time_frame>
    <description>Change of ALT during 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Metabolic Problems</condition>
  <arm_group>
    <arm_group_label>Infrared water group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes drinking water using a tumbler that emits far infrared rays at room temperature for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group takes drinking water using a tumbler at room temperature for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>infrared water group</intervention_name>
    <description>This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.</description>
    <arm_group_label>Infrared water group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sham group</intervention_name>
    <description>This group takes 1,8 L of drinking water using a tumbler at room temperature.</description>
    <arm_group_label>sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years and older

        Exclusion Criteria:

          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than twice the
             highest reference value

          -  serum creatinine â‰¥ 1.5 mg/dL)

          -  uncontrolled diabetes mellitus (a fasting glucose of &gt;160 mg/dL)

          -  uncontrolled hypertension (BP &gt; 160/100 mmHg)

          -  severe gastrointestinal symptoms

          -  alcohol abuser

          -  pregnant or lactating women

          -  allergic to the ingredient involved

          -  cardiocebrovascular diseases or any cancer during the six months prior to study

          -  smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor of Family Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

